Dr. David A. Della Rocca, MD

Dr. Della Rocca practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Della Rocca's NPI, 1639183205, was assigned on July 28, 2006. Dr. Della Rocca graduated from Creighton University School of Medicine - Omaha in 1999. Dr. Della Rocca holds New York license 225562.

Dr. Della Rocca's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Della Rocca's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Della Rocca to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Della Rocca practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Della Rocca's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Della Rocca is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Della Rocca's licenses on file in 2 states: New York and Florida.

Dmand AI lists conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation and vision problems among the conditions Dr. Della Rocca treats.

CMS data shows 668 Medicare services from Dr. Della Rocca across 13 procedure codes in 2024, for 237 Medicare patients. Medicare paid $30,670 for them. Every service was in an office.

CMS counts 237 Medicare patients who saw Dr. Della Rocca in 2024. The largest group is 65 to 74, with 98 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 15% are also on Medicaid. Their average risk score is 1.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Della Rocca's median patient age at 70, with 59% women.

In 2024, Dr. Della Rocca wrote 65 Medicare Part D claims for 40 patients. 74% of them were for generic drugs. CMS names the drug for 19 of them, across 1 drug with 11 or more claims each, at $672 in total drug cost. In 2023, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Della Rocca for performance year 2024, reported as part of a group. Dr. Della Rocca accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Della Rocca as offering telehealth.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 8 papers to Dr. Della Rocca, published from 2012 to 2020. The most frequent topics are Orbital Neoplasms. Dr. Della Rocca's most frequent co-authors are Elizabeth A. Maher, MD, Harsha Reddy, MD and Bruce E. Culliney, MD.

CMS Open Payments shows 3 general payments to Dr. Della Rocca from 3 drug and device companies from 2017 to 2022. Food and beverage make up the largest share, 100% of the total. Mallinckrodt Enterprises LLC paid the most, $144.

Dr. Della Rocca graduated from Creighton University School of Medicine - Omaha in 1999.

Dr. Della Rocca is in network with 11 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.